Mersana Therapeutics (MRSN) to Release Quarterly Earnings on Thursday

Mersana Therapeutics (NASDAQ:MRSN - Get Free Report) will likely be issuing its Q1 2025 quarterly earnings data before the market opens on Thursday, May 8th. Analysts expect the company to announce earnings of ($0.21) per share and revenue of $6.05 million for the quarter.

Mersana Therapeutics (NASDAQ:MRSN - Get Free Report) last posted its quarterly earnings data on Monday, March 3rd. The company reported ($0.11) EPS for the quarter, beating analysts' consensus estimates of ($0.16) by $0.05. Mersana Therapeutics had a negative net margin of 214.20% and a negative return on equity of 401.37%. The company had revenue of $16.36 million during the quarter, compared to analyst estimates of $7.71 million. On average, analysts expect Mersana Therapeutics to post $-1 EPS for the current fiscal year and $-1 EPS for the next fiscal year.

Mersana Therapeutics Trading Down 0.6 %

Mersana Therapeutics stock traded down $0.00 during midday trading on Friday, reaching $0.40. The stock had a trading volume of 1,556,982 shares, compared to its average volume of 2,502,432. Mersana Therapeutics has a twelve month low of $0.26 and a twelve month high of $3.63. The company has a debt-to-equity ratio of 13.35, a current ratio of 2.35 and a quick ratio of 2.35. The firm has a market cap of $49.57 million, a price-to-earnings ratio of -0.65 and a beta of 1.32. The firm's fifty day simple moving average is $0.40 and its two-hundred day simple moving average is $1.13.

Wall Street Analysts Forecast Growth

A number of brokerages have commented on MRSN. Wedbush restated an "outperform" rating and set a $4.00 price objective on shares of Mersana Therapeutics in a research report on Monday, March 3rd. William Blair assumed coverage on shares of Mersana Therapeutics in a research note on Thursday, February 6th. They set an "outperform" rating for the company. One analyst has rated the stock with a hold rating, three have issued a buy rating and one has issued a strong buy rating to the stock. According to data from MarketBeat.com, the company presently has a consensus rating of "Buy" and an average target price of $4.00.

Mersana Therapeutics Company Profile

Mersana Therapeutics, Inc, a clinical stage biopharmaceutical company, develops antibody drug conjugates (ADC) for cancer patients with unmet needs. The company develops XMT-1660, a B7-H4-targeted Dolasynthen ADC candidate; and XMT-2056, an immunosynthen ADC. It has research and development collaborations with Janssen Biotech, Inc, Ares Trading SA, Merck KGaA, and Asana BioSciences, LLC for the development of ADC product candidates.